147 related articles for article (PubMed ID: 9638501)
1. Effects of a neutral endopeptidase inhibitor, BP102, on the development of deoxycorticosterone acetate-salt hypertension in kininogen-deficient Brown Norway Katholiek rats.
Nakajima S; Majima M; Ito H; Hayashi I; Yajima Y; Katori M
Int J Tissue React; 1998; 20(2):45-56. PubMed ID: 9638501
[TBL] [Abstract][Full Text] [Related]
2. Crucial suppressive role of renal kallikrein-kinin system in development of salt-sensitive hypertension.
Katori M; Majima M; Hayashi I
Biol Res; 1998; 31(3):143-9. PubMed ID: 9830501
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms underlying the augmented responses of deoxycorticosterone acetate-salt hypertensive rats to neutral endopeptidase inhibitors.
Hirata Y; Suzuki Y; Suzuki E; Hayakawa H; Kimura K; Goto A; Omata M; Minamino N; Kangawa K; Matsuo H
J Hypertens; 1994 Apr; 12(4):367-74. PubMed ID: 8064160
[TBL] [Abstract][Full Text] [Related]
4. Essential role of kallikrein-kinin system in suppression of blood pressure rise during the developmental stage of hypertension induced by deoxycorticosterone acetate-salt in rats.
Katori M; Majima M; Mohsin SS; Hanazuka M; Mizogami S; Oh-ishi S
Agents Actions Suppl; 1992; 38 ( Pt 3)():235-42. PubMed ID: 1281379
[TBL] [Abstract][Full Text] [Related]
5. Effects of the selective neutral endopeptidase inhibitor, retrothiorphan, on renal function and blood pressure in conscious normotensive Wistar and hypertensive DOCA-salt rats.
Pham I; el Amrani AI; Fournié-Zaluski MC; Corvol P; Roques B; Michel JB
J Cardiovasc Pharmacol; 1992 Dec; 20(6):847-57. PubMed ID: 1282584
[TBL] [Abstract][Full Text] [Related]
6. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension.
Pham I; Gonzalez W; el Amrani AI; Fournié-Zaluski MC; Philippe M; Laboulandine I; Roques BP; Michel JB
J Pharmacol Exp Ther; 1993 Jun; 265(3):1339-47. PubMed ID: 8389863
[TBL] [Abstract][Full Text] [Related]
7. Ebelactone B, an inhibitor of urinary carboxypeptidase Y-like kininase, prevents the development of deoxycorticosterone acetate-salt hypertension in rats.
Majima M; Ikeda Y; Kuribayashi Y; Mizogami S; Katori M; Aoyagi T
Eur J Pharmacol; 1995 Sep; 284(1-2):1-11. PubMed ID: 8549611
[TBL] [Abstract][Full Text] [Related]
8. Effect of prolonged administration of a urinary kinase inhibitor, ebelactone B on the development of deoxycorticosterone acetate-salt hypertension in rats.
Ito H; Majima M; Nakajima S; Hayashi I; Katori M; Izumi T
Br J Pharmacol; 1999 Feb; 126(3):613-20. PubMed ID: 10188971
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of kinin degradation on the luminal side of renal tubules reduces high blood pressure in deoxycorticosterone acetate salt-treated rats.
Nakajima S; Ito H; Hayashi I; Kuribayashi Y; Okumura T; Yajima Y; Katori M; Majima M
Clin Exp Pharmacol Physiol; 2000; 27(1-2):80-7. PubMed ID: 10696533
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic profile of CGS 24128, a potent, long-acting inhibitor of neutral endopeptidase 24.11.
Trapani AJ; Beil ME; Coté DT; de Lombaert S; Erion MD; Gerlock TE; Ghai RD; Hopkins MF; Peppard JV; Webb RL
J Cardiovasc Pharmacol; 1994 Mar; 23(3):358-64. PubMed ID: 7515977
[TBL] [Abstract][Full Text] [Related]
11. Effects of SA7060, a novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme, on deoxycorticosterone acetate-salt-induced hypertension in rats.
Kuro T; Okahara A; Nose M; Ikuse T; Matsumura Y
Biol Pharm Bull; 2000 Jul; 23(7):820-5. PubMed ID: 10919359
[TBL] [Abstract][Full Text] [Related]
12. Role of the renal kallikrein-kinin system in the development of salt-sensitive hypertension.
Katori M; Majima M; Hayashi I; Fujita T; Yamanaka M
Biol Chem; 2001 Jan; 382(1):61-4. PubMed ID: 11258674
[TBL] [Abstract][Full Text] [Related]
13. Host stromal bradykinin B2 receptor signaling facilitates tumor-associated angiogenesis and tumor growth.
Ikeda Y; Hayashi I; Kamoshita E; Yamazaki A; Endo H; Ishihara K; Yamashina S; Tsutsumi Y; Matsubara H; Majima M
Cancer Res; 2004 Aug; 64(15):5178-85. PubMed ID: 15289322
[TBL] [Abstract][Full Text] [Related]
14. Altered regulation of renal sodium transporters and natriuretic peptide system in DOCA-salt hypertensive rats.
Bae EH; Kim IJ; Ma SK; Kim SW
Regul Pept; 2009 Oct; 157(1-3):76-83. PubMed ID: 19422859
[TBL] [Abstract][Full Text] [Related]
15. Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats.
Pu Q; Touyz RM; Schiffrin EL
J Hypertens; 2002 May; 20(5):899-907. PubMed ID: 12011651
[TBL] [Abstract][Full Text] [Related]
16. An ATP-sensitive potassium channel blocker suppresses sodium-induced hypertension through increased secretion of urinary kallikrein.
Kamata Y; Fujita T; Kato T; Hayashi I; Kurosaka M; Katori M; Fujita Y; Majima M
Hypertens Res; 2009 Mar; 32(3):220-6. PubMed ID: 19262486
[TBL] [Abstract][Full Text] [Related]
17. Bradykinin inhibits development of myocardial infarction through B2 receptor signalling by increment of regional blood flow around the ischaemic lesions in rats.
Ito H; Hayashi I; Izumi T; Majima M
Br J Pharmacol; 2003 Jan; 138(1):225-33. PubMed ID: 12522094
[TBL] [Abstract][Full Text] [Related]
18. Role of the renal kallikrein-kinin system in the development of hypertension.
Katori M; Majima M
Immunopharmacology; 1997 Jun; 36(2-3):237-42. PubMed ID: 9228552
[TBL] [Abstract][Full Text] [Related]
19. The role of kinins and atrial natriuretic peptide on the renal effects of neutral endopeptidase inhibitor in normotensive and hypertensive rats.
Nomura N; Shimamoto K; Ura N; Iwata M; Aoyama T; Takagawa Y; Iimura O
Clin Exp Hypertens; 1995 Nov; 17(8):1219-31. PubMed ID: 8563698
[TBL] [Abstract][Full Text] [Related]
20. Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
Duncan AM; James GM; Anastasopoulos F; Kladis A; Briscoe TA; Campbell DJ
J Pharmacol Exp Ther; 1999 Apr; 289(1):295-303. PubMed ID: 10087017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
